For the following articles, the affiliations for author Prof. Paul Emery, should be given as follows: Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds; NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, UK. We regret the error.
Dijkmans B, Emery P, Hakala M, et al. Etanercept in the longterm treatment of patients with ankylosing spondylitis. J Rheumatol 2009;36:1256–64;
Emery P, Genovese MC, van Vollenhoven R, Sharp JT, Patra K, Sasso EH. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol 2009;36:1429–41;
Conaghan PG, Bird P, McQueen, F, et al. The OMERACT MRI Inflammatory Arthritis Group: Advances and future research priorities. J Rheumatol 2009;36:1803–5;
Østergaard M, Conaghan PG, O’Connor P, et al. Reducing invasiveness, duration, and cost of MRI in rheumatoid arthritis by omitting IV contrast injection — Does it change the assessment of inflammatory and destructive joint changes by the OMERACT RAMRIS? J Rheumatol 2009;36:1806–10;
Østergaard M, McQueen F, Wiell C, et al The OMERACT psoriatic arthritis MRI scoring system (PsAMRIS): Definitions of key pathologies, suggested MRI sequences, and preliminary scoring system for psoriatic arthritis hands. J Rheumatol 2009;36:1816–24;
Haque S, Gordon C, Isenberg D, et al. Risk factors for clinical coronary heart disease in systemic lupus erythematosus: The Lupus and Atherosclerosis Evaluation of Risk (LASER) Study. J Rheumatol 2010;37:322–9;
van Vollenhoven RF, Emery P, Bingham CO III, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials J Rheumatol 2010;37:558–67.